Fludarabine

别名: FaraA, Fludarabinum, NSC 118218 中文名称:氟达拉滨

Fludarabine在血管平滑肌细胞中是一种STAT1活化抑制剂,特异性降低STAT1蛋白质水平(和mRNA水平) ,而对其他STATs无此作用。它还是一种DNA合成抑制剂。Fludarabine可诱导凋亡。

Fludarabine Chemical Structure

Fludarabine Chemical Structure

CAS: 21679-14-1

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1032.75 现货
10mg RMB 810.59 现货
50mg RMB 2525.07 现货
200mg RMB 5651.1 现货
1g RMB 7950.08 现货
更大包装 有超大折扣

400-668-6834

info@selleck.cn

免费分装
免费预溶

客户使用Selleck的Fludarabine发表文献175

产品质控

批次: 纯度: 99.96%
99.92

Fludarabine相关产品

相关信号通路图

STAT抑制剂选择性比较

细胞实验数据示例

细胞系 实验类型 给药浓度 孵育时间 活性描述 文献信息
EHEB Apoptosis Assay 40 μM 24 h induces apoptosis 23497075
HEC50B Apoptosis Assay 20/100 μM 24 h induces apoptosis slightly 23595697
AN3CA Apoptosis Assay 20/100 μM 24 h induces apoptosis in a dose-dependent manner 23595697
HEC1A Apoptosis Assay 20/100 μM 24 h induces apoptosis in a dose-dependent manner 23595697
HEC50B Growth Inhibition Assay 100-500 μM 24 h inhibits cell growth slightly 23595697
AN3CA Growth Inhibition Assay 100-500 μM 24 h inhibits cell growth in a dose-dependent manner 23595697
HEC1A Growth Inhibition Assay 100-500 μM 24 h inhibits cell growth in a dose-dependent manner 23595697
Reh Function Assay 10 μM 1/2/4 h induces autophagy 23681223
Nalm-6 Function Assay 10 μM 1/2/4 h induces autophagy 23681223
DU-145 Growth Inhibition Assay 0-10 μg/ml 48 h  inhibits cell growth in a dose-dependent manner 23734815
NALM6 Apoptosis Assay 5 μM 24 h induces cell apoptosis 24057147
I-83 Apoptosis Assay 5 μM 24 h induces cell apoptosis 24057147
BJAB Apoptosis Assay 5 μM 24 h induces cell apoptosis 24057147
HMECs  Function Assay 100 μM  36 h inhibits IFNα mediated phosphorylation of STAT1 and STAT3, but not of STAT2 24211327
HMECs Function Assay 100 μM  36 h inhibits IFNγ and LPS induced STAT1 phosphorylation and IRF1 expression 24211327
624.38mel  Function Assay 50-200 μM 24 h inhibits IDO activity independently of mRNA levels 24911872
MDA-231 Function Assay 50-200 μM 24 h inhibits IDO activity independently of mRNA levels 24911872
624.38mel  Function Assay 50 μM 24 h decreases IDO expression 24911872
MDA-231 Function Assay 100 μM 24 h decreases IDO expression 24911872
PBMC Function Assay 50/100 μM 24 h inhibits STAT1 phosphorylation 24911872
Raji  Function Assay 3 μM 24/48/72 h induces accumulations of p53, p63 and p73  24940695
KBM3/Bu2506 Apoptosis Assay 2.5 μM 48 h induces apoptosis slightly 25111583
MOLM 13 Apoptosis Assay 2.5 μM 48 h induces apoptosis slightly 25111583
THP-1 Apoptosis Assay 2.5 μM 48 h induces apoptosis slightly 25111583
MV-4-11 Apoptosis Assay 2.5 μM 48 h induces apoptosis slightly 25111583
Jeko-1  Function Assay 20 μM 24 h inhibits expression of IDO 25940712
CLL  Apoptosis Assay 10 μM  24-96 h induces apoptotic cell death 22207686
MEC1 Apoptosis Assay 100 μM 72 h induces apoptosis significantly 22132973
U937  Apoptosis Assay 0.8 μM 4-48 h induces apoptosis slightly 22074700
U937  Apoptosis Assay 1 μM 96 h induces apoptosis slightly 22023523
Daudi Apoptosis Assay 20 μM 96 h induces apoptosis slightly 22023523
J45.01 Apoptosis Assay 1 μM 96 h induces apoptosis slightly 22023523
NALM-6 Apoptosis Assay 10 μM  24 h induces cell apoptosis slightly 21699383
JMV-3 Apoptosis Assay 10 μM  24 h induces cell apoptosis slightly 21699383
EHEB Function Assay 5-50 μM 24 h decreases p21 expression significantly 21168391
JVM-2  Function Assay 30 μM 24 h decreases p21 expression 21168391
KBM3/Bu2506 Growth Inhibition Assay 0.6 μM 24 h increases the cell fraction in S-phase 20933509
HLE-B3  Function Assay 25 μM 48 h blocks IFN-γ–induced STAT1 phosphorylation and IDO expression 20435158
SKW6.4 Apoptosis Assay 0.01-10 μM 24/48 h induces cell death in both time- and dose- dependent manner 18092340
CCRF-CEM Function assay 10 uM 1 to 60 mins Drug transport in human CCRF-CEM cells assessed as ENT1-mediated uptake at 10 uM after 1 to 60 mins by liquid scintillation counting analysis 23388705
K562 Growth Inhibition Assay 72 h IC50=3.3 nM 20307198
RPMI 8226 Growth Inhibition Assay 24 h IC50=1.54 μM 17976186
MM.1S Growth Inhibition Assay 48 h IC50=13.48 μM 17976186
MM.1R Growth Inhibition Assay 48 h IC50=33.79 μM 17976186
CLL5 Antitumor assay 48 hrs Antitumor activity against CLL5 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis, EC50 = 0.16 μM. 24673739
K562 Cytotoxicity assay 72 hrs Cytotoxicity against human paclitaxel-resistant K562 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. 20605656
CLL3 Antitumor assay 48 hrs Antitumor activity against CLL3 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis, EC50 = 0.35 μM. 24673739
CLL4 Antitumor assay 48 hrs Antitumor activity against CLL4 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis, EC50 = 0.64 μM. 24673739
CEM-DNR-B Cytotoxicity assay 72 hrs Cytotoxicity against human CEM-DNR-B cells after 72 hrs by MTT assay, IC50 = 1.01 μM. 20605656
CLL6 Antitumor assay 48 hrs Antitumor activity against CLL6 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis, EC50 = 1.6 μM. 24673739
CLL2 Antitumor assay 48 hrs Antitumor activity against CLL2 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis, EC50 = 2.66 μM. 24673739
HCT116 Cytotoxicity assay 72 hrs Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay, IC50 = 6.6 μM. 25462277
PBMC Cytotoxicity assay 48 hrs Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay in presenc of mouse M210B4 cells, IC50 = 10 μM. 25562417
CLL1 Antitumor assay 48 hrs Antitumor activity against CLL1 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis, EC50 = 17.1 μM. 24673739
CEM Cytotoxicity assay 72 hrs Cytotoxicity against human CEM cells after 72 hrs by MTT assay, IC50 = 19.49 μM. 20605656
T47D Cytotoxicity assay 72 hrs Cytotoxicity against human T47D cells after 72 hrs by SRB assay, IC50 = 46.2 μM. 25462277
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 47.44 μM. 20605656
Reh Growth Inhibition Assay IC50 ∼10 μM 23681223
Nalm-6 Growth Inhibition Assay IC50 ∼10 μM 23681223
Nalm-6-FluR Growth Inhibition Assay IC50=250 μM 25061101
Molt-4 Growth Inhibition Assay IC50=180 μM 25061101
RPMI-8226 Growth Inhibition Assay IC50=500 μM 25061101
Mec-1 Growth Inhibition Assay IC50>500 μM 25061101
U2937 Growth Inhibition Assay IC50=16 μM 25061101
Reh Growth Inhibition Assay IC50=30 μM 25061101
Nalm-6 Growth Inhibition Assay IC50=18 μM 25061101
A549 Growth Inhibition Assay IC50=15.7±2.8 µM 23377192
A549 GAPDH-deficient Growth Inhibition Assay IC50=18.5±2.3 µM 23377192
RPMI 8226 Growth Inhibition Assay IC50=25.9 ± 3.7 μM 21948264
CEM Growth Inhibition Assay IC50=2.4 ± 0.4 μM 21948264
Raji Growth Inhibition Assay IC50=0.47 ± 0.04 μM 21948264
U937 Growth Inhibition Assay IC50=0.24 ± 0.04 μM 21948264
K562 Growth Inhibition Assay IC50=0.44 ± 0.05 μM 21948264
KBM3/Bu2506 Growth Inhibition Assay IC20=0.67 µM 20933509
MDA-MB-231 Growth Inhibition Assay IC50=4.0 μM 20447390
MCF-7 Growth Inhibition Assay IC50=15.0 μM 20447390
BW-225 Growth Inhibition Assay IC20=1.37 ×10−8 μM  18661380
OH-65 Growth Inhibition Assay IC20=1.37 ×10−8 μM  18661380
GR-145 Growth Inhibition Assay IC20=2.74 × 10−8 μM  18661380
A549 Growth Inhibition Assay IC20=5.48 × 10−8 μM  18661380
CaSki  Growth Inhibition Assay IC20=1.37 × 10−7 μM  18661380
ZMK-1 Growth Inhibition Assay IC20=1.37 × 10−6 μM  18661380
U937 Growth Inhibition Assay IC50=3,200 ± 560 nM 15930361
primary CLL Cytotoxicity assay Cytotoxicity against human primary CLL cells, LD50 = 1.1 μM. 25148392
CHO Function assay Binding affinity determined by displacement of specific binding of [125I]N-(4-amino-3-iodophenethyl)-adenosine in membranes of CHO cells stably transfected with the rat adenosine A3 receptor, Ki = 10.4 μM. 7707320
JVM2 Antitumor assay Antitumor activity against human JVM2 cells assessed as cell viability after 48 hrs by FACS analysis, EC50 = 10.4 μM. 24673739
HeLa Antitumor assay Antitumor activity against human HeLa cells assessed as cell viability by MTT assay, EC50 = 16 μM. 24673739
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells 29435139
Daoy qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells 29435139
点击查看更多细胞系数据

生物活性

产品描述 Fludarabine在血管平滑肌细胞中是一种STAT1活化抑制剂,特异性降低STAT1蛋白质水平(和mRNA水平) ,而对其他STATs无此作用。它还是一种DNA合成抑制剂。Fludarabine可诱导凋亡。
靶点
STAT1 [4]
(Vascular smooth muscle cells)
体外研究(In Vitro)
体外研究活性

Fludarabine有效抑制RPMI8226细胞增殖,呈时间浓度依赖性。Fludarabine处理MM.1S和MM.1R细胞48小时的IC50分别为13.48μg/mL和33.79μg/mL。而Fludarabine处理U266细胞48小时的IC 50为222.2μg/mL。Fludarabine处理可增加处于细胞周期G 1期的细胞数量,并伴随着处于细胞周期S期细胞数量的减少,对细胞周期的影响呈时间依赖性。Fludarabine在MM细胞中诱导细胞周期阻滞和细胞凋亡。Fludarabine时间依赖性的诱导caspase,-8,- 9和- 3,- 7的剪切,继而诱导PARP的剪切 。氟达拉滨以时间梯度增加Bax基因表达,而Bak基因表达量不变。RPMI 8226细胞用Fludarabine处理12小时,处理后细胞膜电位降低,61.05%的细胞表达低荧光罗丹明123,而未处理的对照组细胞仅为8.62%[1]。为提高溶解度,Fludarabine可制为一磷酸盐形式(F-ara-AMP, fudarabine),在静脉滴注后即可即时、定量的从母核上去磷酸化。细胞内重磷酸化修饰导致Fludarabine-阿糖胞苷三磷酸((F-ara-ATP)。该代谢产物抑制了DNA复制的几个关键过程,如DNA合成所需酶,比如核糖核酸还原酶,DNA引发酶,DNA聚合酶,具有3 ' - 5 '外切酶活性的脱氧核糖核酸聚合酶δ和ε和DNA连接酶[2]。通过检测ICAM - 1的表达和IL - 8释放,表明Fludarabine还可以诱导前炎症刺激单核细胞的增加[3]。Fludarabine对卵巢癌细胞系生长无影响,而它对黑色素瘤细胞系有明显的剂量依赖性抑制[4]。Fludarabine是一种STAT1抑制剂,可特异性降低STAT1而不影响STAT1家族的其他成员[5]。除了细胞质积累外,重复低剂量顺铂(RLDC)还诱导HMGB1表达,该表达被STAT1敲除明显抑制。Fludarabine在RLDC治疗的肾小管细胞中始终呈剂量依赖性地抑制HMGB1的表达[5]

细胞实验 细胞系 地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系
浓度 2 μg/Ml
孵育时间 24 小时
方法

对地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系以5 × 105细胞密度铺板,实验组均包括氟达拉滨处理和空白对照组。处理后细胞用PBS清洗两次然后用70%冰乙醇固定,离心后用含100μg/mL核糖核酸酶PBS重悬浮,37ºC孵育30分钟。样品重悬于25μg/mL碘化吡啶中,用流式细胞仪检测。根据产品说明用Annexin V-FITC试剂盒检测细胞凋亡。利用TUNEL(末端脱氧核苷酸转移酶介导脱氧核苷酸缺口末端标记)法和原位细胞凋亡检测试剂盒处理细胞,最后用流式细胞仪分析。

实验图片 检测方法 检测指标 实验图片 PMID
Western blot procaspase-9 / procaspase-3 p-p53 / p53 STAT1 27223263
Immunofluorescence α-SMA / Vimentin 28322315
Growth inhibition assay Cell viability 24956101
体内研究(In Vivo)
体内研究活性

PBS对照组中肿瘤细胞增长迅速,25天内扩增为10倍。而用40mg/kgFludarabine处理的肿瘤扩增不超过5倍。40mg/kgFludarabine对RPMI 8226细胞有明显的抗肿瘤效果。RPMI 8226处理肿瘤细胞十天后增加凋亡细胞核数量。[1] Fludarabine可在免疫缺陷小鼠中有效抑制RPMI 8226细胞的骨髓转移。

动物实验 Animal Models 携带RPMI 8226肿瘤细胞的免疫缺陷型小鼠
Dosages 40 mg/kg
Administration 腹腔注射
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05390814 Not yet recruiting
Primary Central Nervous System Lymphoma
Assistance Publique - Hôpitaux de Paris
February 15 2024 Phase 1
NCT05201183 Withdrawn
Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Lymphocytic Leukemia|Myelodysplastic Syndromes
Naoyuki G. Saito M.D. Ph.D.|Indiana University
October 2023 Phase 1|Phase 2
NCT05917405 Recruiting
Acute Myeloid Leukemia in Remission
Nantes University Hospital
September 14 2023 Phase 2
NCT05290662 Recruiting
AML
Glycostem Therapeutics BV
June 14 2022 --

化学信息&溶解度

分子量 285.23 分子式

C10H12FN5O4

CAS号 21679-14-1 SDF Download Fludarabine SDF
Smiles C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N
储存条件(自收到货起)

体外溶解度
批次:

DMSO : 57 mg/mL ( 199.83 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次:

现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量 浓度 体积 分子量

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
how to re-suspend and deliver the inhibitor for in vivo experiments?

回答:
For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

Tags: buy Fludarabine | Fludarabine supplier | purchase Fludarabine | Fludarabine cost | Fludarabine manufacturer | order Fludarabine | Fludarabine distributor
在线咨询
联系我们